Crysvita (burosumab-twza)

Crysvita (burosumab‑twza) is covered only for X‑linked hypophosphatemia (XLH) in patients aged ≥6 months when specified baseline diagnostic criteria are met; other uses are excluded. Approval (up to 12 months) requires pre‑treatment serum phosphorus below age norms plus either low TmP/GFR or a PHEX mutation, adults (≥18) must be symptomatic and have trialed oral phosphate and calcitriol unless contraindicated, therapy must be prescribed by or with an endocrinologist/nephrologist, dosing is weight‑based with a 90 mg max per dose, and reauthorization requires documented clinical benefit.

"Treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older (FDA-approved indication)."

Sign up to see full coverage criteria, indications, and limitations.